کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3995377 | 1258938 | 2008 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?](/preview/png/3995377.png)
SummaryOn the basis of preclinical studies that show overexpression of class III β-tubulin is associated with resistance to tubulin-binding agents, several investigators have addressed the relation between class III β-tubulin and outcome in patients treated with such agents. High expression of class III β-tubulin has been found to be correlated either with low response rates in patients treated with regimens containing taxanes or vinorelbine or with reduced survival in patients with non-small-cell lung cancer, in breast, ovarian, and gastric cancers, and in cancers of unknown primary site. Two studies have shown patients with advanced non-small-cell lung cancer receiving paclitaxel whose tumours expressed high levels of class III β-tubulin had a lower response to paclitaxel and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without tubulin-binding agents. Conversely, analysis of samples from patients in the JBR-10 trial, which compared adjuvant chemotherapy to no further therapy in operable non-small-cell lung cancer, showed that chemotherapy seemed to overcome the negative prognostic effect of high levels of expression of class III β-tubulin and the greatest benefit from cisplatin/vinorelbine was seen in patients with high levels of expression of class III β-tubulin. Further analyses in operable and advanced non-small-cell lung cancer showed a relation between high expression of class III β-tubulin and baseline factors such as age under 60 years, adenocarcinoma and large-cell carcinoma histologies, and advanced stage of disease. These results suggest that class III β-tubulin could be both a prognostic and a predictive factor. Large randomised studies are warranted to determine the prognostic or predictive value of class III β-tubulin in different settings and tumours.
Journal: - Volume 9, Issue 2, February 2008, Pages 168–175